Dr. Oh-Lee

Dr. Oh-Lee received a B.A. degree from Colorado College and his Master’s & Ph.D. degree from the University of California, Los Angeles (UCLA) where he worked on the nerve growth factor receptor, p75, in Alzheimer’s disease pathogenesis. For postdoctoral training, he received an Intramural Research Training Award (IRTA) fellowship (1995-1999) and worked as a research fellow (1999-2001) at the Clinical Pharmacology Section, Experimental Therapeutics Branch, NINDS, National Institutes of Health, Bethesda, Maryland, studying neurobiological and neuropharmacological basis of motor and response complications in Parkinson’s disease. He joined the Department of Psychology at Central Michigan University (CMU) as an assistant professor in 2001 where he now serves as a Co-director of the BRAIN Center at CMU. His current research interests include studies in neuronal plasticity and neuronal degenerative processes, particularly those that are associated with neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and other related neurological diseases.

Recent Publications (last 3 yrs.) & Awards, Honors, Etc.:

Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD. (2004) NR2B Selective NMDA Receptor Antagonist CP-101,606 Prevents Levodopa-Induced Motor Response Alterations in Hemiparkinsonian Rats. Neuropharmacology, 47, 184-194.

Bibbiani F and Oh JD. (2004) Animal Models of Movement Disorders, Motor Complications in Primate Models of Parkinson’s Disease. in press.

Bibbiani F and Oh JD, Petzer JP, Castagnoli N, Chen J-F, Schwarzchild MA, and Chase TN. (2003) A_2A antagonist prevents dopamine agonist-induced motor complications in animal models of PD. Experimental Neurology, 184(1), 285-294.

Chase TN, Bibbiani F, Bara-Jimez W, Dimitrova T, Oh JD. (2003) Translating A2a antagonist KW-6002 from animal models to parkinsonian patients. Neurology, 61 (6), S107-S111.

Oh JD, Chartisathian K, Ahmed SM, and Chase TN. (2003) Cyclic AMP responsive element binding protein (CREB) Phosphorylation and Persistent Expression of Levodopa-induced Response Alterations in Parkinsonian Rats. Journal of Neuroscience Research, 72, 768-780.

Oh JD, Geller AI, Zhang GR, Chase TN. (2003) Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Research, 971(1), 18-30.

Chase TN, Bibbiani F, Oh JD. (2003) Striatal Glutamatergic Mechanisms and Extrapyramidal Movement Disorders. Neurotoxicity Research, 5(1-2), 139-146.

Oh JD, PhD, Francesco Bibbiani, MD, Thomas N. Chase, MD. (2002) Quetiapine Attenuates Levodopa-induced Motor Complications in Rodent and Primate Parkinsonian Models. Experimental Neurology 177(2), 557-564.

Metman LV and Oh JD. (2002) Dyskinesias in Parkinson’s Disease; Ionotrophic Glutamate Receptors as Therapeutic Targets (Ed: Lodge D.; Danysz W.; Parsons CG), pp. 205-225, F.P. Graham Publishing Co., Johnson City, Tennessee.

Oh JD and Chase TN (2002) Glutamate-mediated striatal dysregulation and pathogenesis of Parkinsonian motor response complications, Amino Acids, 23, 133-139.

Bibbiani F; Oh JD; Chase TN. (2002) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology, Vol 58, Iss 7, pp A373-A373

Chase TN; Konitsiotis S; Oh JD. (2001) Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Advances In Neurology: PARKINSON'S DISEASE, Vol 86, pp 355-360

Bibbiani F, Oh JD, Chase TN, (2001) Serotonin 5-HT1A agonist, sarizotan, attenuates levodopa-induced motor complications in rodent and primate parkinsonian models, Neurology, 57, 1829-1834.

Zhong LT, Manzi A, Skowronski E, Notterpek L, Fluharty AL, Faull KF, Masada I, Rabizadeh S, Varsanyi-Nagy M, Ruan YL, Oh JD, Butcher LL, Bredesen DE, (2001), A monoclonal antibody that induces neuronal apoptosis binds a metastasis marker, Cancer Research, 61(15), 5741-5748.

Honors, Awards and Distinctions:

June, 1986 Graduated with Distinction in Chemistry from Colorado College.

1989 - 1990 National Institute of Mental Health Trainee Fellowship.

1990 - 1991 UCLA Graduate Division Travel Grant Research Award.

1989 - 1993 UCLA President AA Fellowship Award.

1989 - 1992 Academic Guidance Service member, Los Angeles, CA

1991 - 1995 Private tutor in science, math, martial arts (Tae Kwon Do).

1992 - 1994 Psychology Graduate Student Association (PGSA) member.

1992 - 1994 PGSA representative for Behavioral Neuroscience area.

1992 - 1994 PGSA Graduate Affairs Committee representative alternate.

1993 - 1994 PGSA secretary.

1989 - 1999 Member of Society of Neuroscience

1992 - 1999 Member of American Association for the Advancement of Science

June, 1993 The College of Letters and Science Graduate Student Award,

UCLA.

1994 - 1995 UCLA Graduate Division Award for conference travel support

1996 - 1999 Animal Care and Use Committee representative for the

experimental therapeutic branch, NINDS, NIH.

April, 1999 Received a plaque for distinguished Services to NINDS ACUC, NIH.

1999 – 2000 Outstanding Research Award from Association of Korean

Neuroscientist Research Award.

March, 2000 Special Act/Service Award from U.S. Dept. of Health and Human

Services, Public Health Service, National Institutes of Health.

June, 2000 Honorary Recognition for Outstanding Research from National

Institute of Neurological Disorders and Stroke.

2001-2002 President’s Research Investment Fund grant. Effects of bone marrow stem cell on levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Central Michigan University.

Feb., 2003 Research Professorship Award, Central Michigan University.

May., 2003 Summer Faculty Scholars Award, CHSBS, Central Michigan University

July, 2003 National Parkinson Foundation Center of Excellence Fellowship Award